TMC310911 - 10mM in DMSO , CAS No.1000287-05-7

CAS: 1000287-05-7 Cat. No.: T656410 Formule: C₃₈H₅₃N₅O₇S₂ Poids moléculaire: 755.99 PubChem CID: 53361968

QUALITÉ & PURETÉ 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Vue d’ensemble

TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC 50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1 . TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity

In Vitro

For a panel of 2,011 recombinant isolates with decreased susceptibility to at least one of the currently approved protease inhibitors (PIs), the FC in TMC310911 EC 50 is ≤4 for 82% of isolates and ≤10 for 96% of isolates. The fold change (FC) in TMC310911 EC 50 is ≤4 and ≤10 for 72% and 94% of isolates with decreased susceptibility to Darunavir, respectively. In vitro resistance selection (IVRS) performed with r13025, a multiple-PI-resistant recombinant isolate, and TMC310911 selected for mutations L10F, I47V, and L90M (FC in TMC310911 EC 50 = 16). The TMC310911 EC 50 values against HIV-1/LAI and HIV-2/ROD in MT4 cells with EC 50 values of 14.2 nM and 2 nM, respectively, and HIV-1/LAI and HIV-1/SF2 in PBMCs with EC 50 values of 2.2 nM and 2.3 nM, respectively, and HIV-1/BaL in M/M cells with an EC 50 value of 13.9 nM. And the corresponding EC 90 values ranged from 5.0 to 94.7 nM. The TMC310911 CC 50 for MT4 cells is 9.9 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:EC50: 2.2-14.2 nM (Wild-type HIV-1)

Spécifications

Spécifications et pureté

10mM in DMSO

Mécanismes biochimiques et physiologiques

TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC 50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1 . TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong a

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Noms et identifiants

Isomères SMILES

CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7

CAS alternatif

1000287-05-7

PubChem CID

53361968

Termes d'entrée MeSH

((3aS,4R,6aR)-2,3,3a,4,5,6a-Hexahydrofuro(2,3-b)furan-4-yl) N-((1S,2R)-1-benzyl-3-((2-((1-cyclopentyl-4-piperidyl)amino)-1,3-benzothiazol-6-yl)sulfonyl-isobutyl-amino)-2-hydroxy-propyl)carbamate;ASC-09;ASC09;TMC-310911;TMC310911

Poids moléculaire

755.99

Application Protocols

No proprietary, item-specific protocols are provided for this product.

• General workflow suggestions for small-molecule inhibitor studies:
  • Prepare fresh DMSO stocks; verify concentration by UV or quantitative NMR if high accuracy is needed.
  • For enzymatic assays, preincubate inhibitor with HIV-1 protease to reach binding equilibrium before substrate addition if appropriate for the mechanism.
  • Run full concentration–response curves with technical replicates and vehicle controls; apply appropriate models (four-parameter logistic) for IC50 estimation.
  • In cell studies, include cytotoxicity controls and verify compound exposure (LC-MS of media/cell lysate) to interpret pharmacological readouts.
• For chromatography reference use:
  • Establish retention time windows and MS transitions (MRM/PRM) empirically; collision energies should be optimized per instrument.
• Any specific dilutions, positive controls, or antibody-oriented applications are not applicable or not specified for this item.

Biological Roles

• Role (literature): TMC310911 is reported in the literature as a potent small-molecule inhibitor of HIV-1 protease, a dimeric aspartyl protease responsible for processing Gag and Gag-Pol polyproteins during viral maturation.
• Mechanistic context:
  • HIV-1 protease inhibitors bind in the active site and disrupt cleavage of viral polyproteins, yielding immature, noninfectious virions in cellular systems. Binding typically leverages hydrogen bonding to catalytic residues/water network and hydrophobic occupancy of S1/S2 pockets (class description).
• Research utility:
  • Reference inhibitor for enzymology assays (Ki/IC50 determination), resistance mutation profiling, and comparative SAR vs. approved protease inhibitors.
  • Useful for evaluating drug–drug interaction liabilities at the level of efflux transporters and metabolic stability in microsomes/hepatocytes (general for this inhibitor class).
• Selectivity considerations:
  • Designed for HIV-1 protease; off-target profiles should be established empirically using biochemical panels. Literature for the class suggests limited activity on human aspartyl proteases at assay-relevant concentrations, but confirm for this item.
• Note: No medical or therapeutic claims are made. This product is supplied strictly for research use only.

Buffer Applications

This compound is not a buffering agent. It does not serve as an acid/base pair for pH control. For biochemical assays involving HIV-1 protease:

• Use established protease assay buffers (general guidance):
  • Typical components include acetate, MES, or phosphate buffers in the mildly acidic to neutral range, with salt and glycerol or nonionic detergents to stabilize enzyme.
  • Maintain low organic cosolvent (e.g., ≤1–2% DMSO) to keep the inhibitor in solution while preserving enzyme activity.
• Item-specific buffering parameters: Not applicable; refer to your assay protocol and enzyme supplier recommendations.

Green Alternatives

Because this item is a research-grade small-molecule inhibitor (not a solvent or reagent), “green alternatives” center on handling and solvent choices rather than replacing the compound itself.

• Greener handling choices (general):
  • Prefer DMSO or ethanol for stock solutions over higher-toxicity dipolar aprotics (DMF, NMP) when assay-compatible.
  • Use acetonitrile-water gradients for LC where possible instead of chlorinated eluents.
  • Minimize single-use plastics by adopting glass vials with PTFE-lined caps for stock storage.
• Comparison of common solvents for drug-like molecules (general):
  • DMSO: high solvency, low volatility; good EHS profile relative to DMF/NMP; may require glove-change protocol due to skin permeation.
  • Ethanol: renewable origin options; higher volatility; watch aqueous precipitation.
  • 2-Propanol/MeOH: effective but consider toxicity and flammability; MeOH is more toxic than EtOH.
• Process scale considerations:
  • If using this scaffold in medicinal chemistry campaigns, consider convergent routes that reduce protecting-group steps and employ catalytic couplings in greener solvents (e.g., 2-MeTHF or water-compatible systems) per green chemistry principles.

Pharmaceutical Uses

• Regulatory/compendial status: Not specified for this item; not provided as a pharmacopeial-grade substance.
• Research/formulation context (non-clinical):
  • May be used as a reference standard or tool compound during preformulation studies (solubility screening, solid-state characterization, excipient compatibility) to support in vitro research.
  • If exploring enabling formulations for in vitro studies, approaches such as cosolvent systems, amorphous solid dispersions, or cyclodextrin complexes can be evaluated. Confirm stability and activity retention after formulation stress.
• No therapeutic or clinical claims are made. This product is supplied for research use only and is not intended for human or veterinary use.
• Any in vivo or GLP-related applications require appropriate validation, documentation, and grades not covered by this listing.

Physical Properties

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not applicable/Not determined for complex drug-like solids; Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility:
  • Aqueous: Not specified for this item; refer to CoA/Spec Sheet.
  • Organic: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable for solids; Not specified for this item.
• Notes for users (general guidance, literature/class-based): HIV-1 protease inhibitors are frequently lipophilic, often handled as DMSO stocks for biochemical assays. Verify actual solubility and extinction coefficients for this specific lot on the CoA before quantitative use.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
• What this means for users:
  • Without an explicit grade, rely on the CoA for assay purity (e.g., HPLC area %), identity confirmation (NMR/MS), water content, and residual solvent profile. Do not assume pharmacopoeial compliance.
  • For screening library or medicinal chemistry use, typical acceptance criteria include high chromatographic purity and single major component by MS; verify against the provided CoA.
• Stabilizers: Not specified for this item; refer to CoA/Spec Sheet. If none are listed, assume neat compound and protect from moisture/oxidation per SDS.
• UV profile/LC-MS suitability: Not specified for this item; refer to CoA/Spec Sheet. If performing quantitative LC-UV, establish λmax and response factors empirically.
• Batch-to-batch: Request a lot-specific CoA for exact purity, identity methods, and any counter-ion/solvate content that may influence mass and assay calculations.

Reaction and Applications

This product is a finished small-molecule inhibitor intended for research use rather than a synthetic reagent. As such, classical “reaction applications” (e.g., as a catalyst, base, or solvent) do not typically apply.

• Research applications (general, literature):
  • Tool compound for in vitro studies of HIV-1 protease inhibition, enzymology, resistance profiling, and structure–activity relationship benchmarking against reference inhibitors.
  • May serve as a positive control in protease assay development, protein–ligand binding methods (SPR/ITC), or cell-based antiviral mechanism studies. Verify permeability and cytotoxicity conditions independently.
• If using in chemical biology:
  • Confirm purity and identity before quantitative work (HPLC-UV/MS, NMR).
  • Establish solubility and ensure compound remains in solution at working concentrations to avoid underestimating activity.
• Synthetic transformations of this specific molecule are not generally pursued in routine labs; if derivatization is desired for probe development (e.g., tags, linkers), map modifiable positions using the primary literature for this scaffold class.

Reaction Conditions

Classical reaction conditions (solvents, catalysts, temperatures) are not applicable because this material is supplied as a final bioactive compound rather than a reagent. For biological experiments (general guidance):

• Stock preparation:
  • Prepare concentrated stocks (e.g., 10–50 mM) in dry DMSO when compatible with your assay. Filter or centrifuge to remove particulates.
  • Verify compound stability at room temperature and under assay light conditions; minimize repeated freeze–thaw cycles.
• Assay conditions (general):
  • Maintain final DMSO at low percentage (commonly ≤1–2% v/v) in enzyme or cell assays.
  • Include vehicle controls and confirm linear enzyme kinetics under the chosen substrate/enzyme concentrations before potency determination.
• Stability checks:
  • Monitor by LC-MS over the assay time course to ensure no degradation or adsorption losses.
• Note: Item-specific kinetic constants, solubility limits, and stability data are not provided; consult the literature and generate internal data under your exact conditions.

Safety and Handling

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.
• General precautions (good lab practice):
  • Handle in a chemical fume hood; avoid inhalation and contact with skin/eyes.
  • Wear appropriate PPE: lab coat, safety glasses, and nitrile gloves. Change gloves frequently when handling DMSO solutions (many drug-like molecules readily permeate some glove materials).
  • Avoid dust generation when weighing dry solids. Use antistatic tools and closed weigh boats.
• Incompatibilities: Strong oxidizers and strong acids/bases may degrade peptidomimetic scaffolds; avoid prolonged exposure to moisture and light unless stability is documented on the CoA/SDS.
• First aid overview (consult SDS for details):
  • Inhalation: Move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: Rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention if irritation develops.
  • Ingestion: Rinse mouth; do not induce vomiting; obtain medical attention.
• Waste: Collect organic solutions and solids in appropriate hazardous waste streams per institutional and local regulations.
• Authoritative reference: Always defer to the product SDS for definitive hazard, exposure limits, and emergency procedures.

Solvent Selection

• Practical considerations (general guidance for drug-like protease inhibitors):
  • Screening stock solutions are commonly prepared in anhydrous DMSO due to broad solvating power for lipophilic, heteroatom-rich scaffolds.
  • For aqueous work, cosolvents (DMSO ≤1–2% v/v in final assays), or solubilization aids (surfactants, cyclodextrins, or serum proteins) are often used. Confirm no assay interference.
• Miscibility/polarity context (general):
  • DMSO: polar aprotic, high dielectric; excellent for stocks and LC sample prep.
  • DMF/NMP: strong solvents but higher tox profile; reserve for synthetic use, not bioassays.
  • Ethanol/Acetonitrile: useful for intermediate polarity; blend with buffer as needed.
  • Aqueous buffers: use only after establishing kinetic solubility and avoiding precipitation.
• Selection tips:
  • Start with small-scale solubility screens (DMSO, MeCN, EtOH, 50:50 MeCN:H2O) at target concentrations.
  • Filter or centrifuge stock solutions to remove particulates prior to assay or LC injection.
• Item-specific solubility: Not specified for this item; refer to CoA/Spec Sheet. Establish experimental solubility curves if quantitative potency or PK assays are planned.

Storage and Reconstitution

• Storage (item-specific): Store at -80°C.
• Shipping (item-specific): Shipped on dry ice packs + cold packs to preserve material integrity during transit.
• Long-term handling:
  • Keep tightly sealed in original container. Protect from moisture and light as a prudent precaution for drug-like, heteroatom-rich molecules.
  • Upon receipt, allow the sealed container to equilibrate to room temperature before opening to avoid moisture condensation.
• Reconstitution:
  • Recommended solvent and concentration: Not specified for this item; refer to CoA/Spec Sheet. In general for protease inhibitors, anhydrous DMSO is commonly used to prepare concentrated stocks.
  • Mix gently to dissolve; if needed, sonicate briefly or warm slightly (e.g., to room temperature) while avoiding prolonged heating.
  • After reconstitution, aliquot into single-use vials to minimize freeze–thaw cycles.
• Stability after reconstitution: Not specified for this item; establish in-house by LC-MS/HPLC over intended storage times (e.g., -20°C or -80°C).
• Research use note: For research use only. Not for human or veterinary use.

Structure and Identity

• Item identity: TMC310911 (also known in literature as an HIV-1 protease inhibitor candidate).
• CAS: 1000287-05-7
• CID: 53361968
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Structural features (general, literature): TMC-class protease inhibitors are peptidomimetic HIV-1 protease binders that typically incorporate multiple hydrogen-bond donors/acceptors and hydrophobic motifs to engage the active-site flap region. Specific ring systems and stereochemistry for this item are not provided in the product data.
• 2D structure description (general): Expected to comprise a central scaffold bearing polar functionality (often secondary alcohol/amide/sulfonamide motifs in this inhibitor class) flanked by lipophilic substituents that occupy the S1/S2 and S1’/S2’ pockets of HIV-1 protease (literature, class description).

Synthetic Utility

As a finished, complex small-molecule inhibitor, this compound is not typically used as a building block or reagent in synthesis.

• If derivatization is desired for probe development (general guidance):
  • Map noncritical substituents based on literature SAR for this scaffold class to introduce reporter handles (e.g., alkynes/azides for click chemistry, fluorophores, biotin) while preserving protease binding.
  • Protect functional groups susceptible to hydrolysis or oxidation during late-stage functionalization and use chemoselective coupling methods to avoid core scaffold modification.
• Purification/analysis suggestions:
  • Reverse-phase preparative HPLC with water–acetonitrile (0.1% formic acid or ammonium formate, as compatible) is standard for drug-like molecules.
  • Confirm structure by HRMS and multidimensional NMR (HSQC/HMBC) if any modifications are performed.
• For routine synthetic chemistry tasks (couplings, condensations, catalysis), select other dedicated reagents; this product is not designed for that role.

Target Specificity

Target specificity details (e.g., antigen, epitope, species reactivity, clone, isotype) apply to biological macromolecules such as antibodies and are not applicable to this small-molecule product.

• Item-specific target data provided: Not specified for this item; refer to primary literature for HIV-1 protease inhibitor profiling if needed.

Foire aux questions

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 1000287-05-7, the molecular formula is C38H53N5O7S2, and the molecular weight is 755.99 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.